Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$2.55M$2.55M+568.5% vs Q2 2017 Net Income-$4.22M-$4.22MN/M vs Q2 2017 EPS Diluted-$0.03-$0.03N/M vs Q2 2017 Gross Profit$2,441,000+549.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,400,000N/M Free Cash Flowderived-$7,439,000N/M Margins · derivedGross margin95.8%−2.8 pt vs Q2 2017
Operating margin-359.0%+2349.1 pt vs Q2 2017
Net margin-165.5%+2892.5 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 2, 2018 · 33 d after period end